Alterity reanalysis puts MSA drug at 52% slowing
Adjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial began. Alterity Therapeutics has a number it would like you to remember, and the number is 52. That’s the percentage by which its experimental drug ATH434 slowed functional de
<p>Adjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial began. Alterity Therapeutics has a number it would like you to remember, and the number is 52. That’s the percentage by which its experimental drug ATH434 slowed functional de</p>